How much should we invest in antibiotics? Investigating their option value

Research output: Contribution to conferenceAbstractpeer-review


The existing business models for antibiotics fail to promote antibiotics stewardship to preserve our existing portfolio of drugs, while at the same time funding for research and development has been insufficient in recent decades, as only two novel classes of antibiotics have been introduced since the 1970s. The UK is considering novel mechanisms for paying for antibiotics to overcome these issues. We will explore the option value for preserving novel antibiotics for extreme events. We will discuss the option value implications for investment in new antibiotics and possible extensions to the model.
Original languageEnglish
Publication statusPublished - 29 Jul 2019
EventINFORMS Healthcare 2019 - Massachusetts Institute of Technology (MIT), Cambridge, United States
Duration: 26 Jul 201930 Jul 2019


ConferenceINFORMS Healthcare 2019
Country/TerritoryUnited States
Internet address


  • healthcare management
  • antibiotics
  • drug investment


Dive into the research topics of 'How much should we invest in antibiotics? Investigating their option value'. Together they form a unique fingerprint.

Cite this